C. Johnstone

发表

A quantitative assessment of hERG liability as a function of lipophilicity.

M. Waring, C. Johnstone, 2007, Bioorganic & medicinal chemistry letters.

Creativity, innovation and lean sigma: a controversial combination?

Garry Pairaudeau, G. Pairaudeau, Jonas A Pettersson, 2011, Drug discovery today.

Discovery, synthesis and biological evaluation of novel glucokinase activators.

Scott Boyd, G. Currie, B. Hayter, 2005, Bioorganic & medicinal chemistry letters.

Predictive blood glucose lowering efficacy by Glucokinase activators in high fat fed female Zucker rats

C. Allott, M. Coghlan, D. Mckerrecher, 2006, British journal of pharmacology.

Discovery of a series of indan carboxylic acid glycogen phosphorylase inhibitors.

A. Plowright, N. Selmi, P. Kenny, 2010, Bioorganic & medicinal chemistry letters.

A stable catalyst of the Pauson–Khand annelation

C. Johnstone, S. Gibson, A. Stevenazzi, 2002 .

The application of polymer-bound carbonylcobalt(0) species in linker chemistry and catalysis.

N. Hales, C. Johnstone, Alex C. Comely, 2003, Organic & biomolecular chemistry.

Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors.

J. Kendrew, P. Plé, J. Curwen, 1999, Journal of medicinal chemistry.

Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors.

S. Wedge, J. Kendrew, Andrew P Thomas, 2002, Journal of medicinal chemistry.

Development of modified Pauson-Khand reactions with ethylene and utilisation in the total synthesis of (+)-taylorione

C. Johnstone, W. Kerr, Udo E W Lange, 1996 .

Development of dirhodium(II)-catalyzed generation and enantioselective 1,3-dipolar cycloaddition of carbonyl ylides.

C. Johnstone, D. M. Hodgson, A. Labande, 2001, Chemistry.

Catalytic enantioselective tandem carbonyl ylide formation-cycloaddition

C. Johnstone, D. M. Hodgson, P. Stupple, 1997 .

Efficient RhII binaphthol phosphate catalysts for enantioselective intramolecular tandem carbonyl ylide formation–cycloaddition of α-diazo-β-keto esters

C. Johnstone, D. M. Hodgson, P. Stupple, 1999 .

Selective cleavage of ketals and acetals under neutral, anhydrous conditions using triphenylphosphine and carbon tetrabromide

James S. Scott, C. Johnstone, W. Kerr, 1996 .

Total synthesis of (+)-taylorione utilising modified Pauson–Khand reaction methodology

C. Johnstone, W. Kerr, Udo E W Lange, 1995 .

Novel structures and Pauson-Khand activities of N-Heterocyclic carbene dicobalt complexes

J. Loch, J. Steed, C. Johnstone, 2003 .

A new approach to functionalized spiropiperidines through tandem RCM and nitrogen-directed reactions.

H. Adams, C. Johnstone, Andrew S. Edwards, 2002, Chemical communications.

A diastereoselective tandem RCM approach to spiropiperidines

Neil G. Stevenson, H. Adams, C. Johnstone, 2004 .

A new approach to functionalised spiropiperidines through tandem RCM and nitrogen-directed reactionsElectronic supplementary information available: experimental procedures and data for all new compounds. See http://www.rsc.org/suppdata/cc/b2/b203851j/

H. Adams, C. Johnstone, Andrew S. Edwards, 2002 .

A Diastereoselective Tandem RCM Approach to Spiropiperidines.

Neil G. Stevenson, H. Adams, C. Johnstone, 2005 .

Understanding and Improving Platinum Anticancer Drugs

S. Lippard, Ga-Young Park, C. Johnstone, 2014 .

Hypothesis driven drug design: improving quality and effectiveness of the design-make-test-analyse cycle.

R. A. Thompson, Jonas Pettersson, Jan Kihlberg, 2012, Drug discovery today.

Design of a potent, soluble glucokinase activator with increased pharmacokinetic half-life.

D. Mckerrecher, C. Johnstone, Craig S Donald, 2011, Bioorganic & medicinal chemistry letters.

Property based optimisation of glucokinase activators – discovery of the phase IIb clinical candidate AZD1656

Michael J. Waring, Graeme R. Robb, David S. Clarke, 2012 .

Making medicinal chemistry more effective--application of Lean Sigma to improve processes, speed and quality.

Nidhal Selmi, Jan Kihlberg, Magnus J. Johansson, 2009, Drug discovery today.

Design of a potent, soluble glucokinase activator with excellent in vivo efficacy.

D. Mckerrecher, C. Johnstone, Keith M Johnson, 2006, Bioorganic & medicinal chemistry letters.

Enantioselective intramolecular 1,3-dipolar cycloadditions of diazocarbonyl-derived oxidopyryliums

C. Johnstone, P. Stupple, D. Hodgson, 2003 .

Matrix-based multiparameter optimisation of glucokinase activators: the discovery of AZD1092

Michael J. Waring, Graeme R. Robb, M. Waring, 2011 .

Abstract 3970: Targeting the adenosine immunosuppressive pathway for cancer immunotherapy with small molecule agents

A. Hopkins, A. Schreyer, M. Whittaker, 2017 .

Medicinal chemistry matters - a call for discipline in our discipline.

C. Johnstone, 2012, Drug discovery today.